Document text
Principal Investigator: Richard Davey
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2020
Award: $3,487,152
Funding agency: National Institute of Allergy and Infectious Diseases
The FLU 003 Plus (Respiratory Virus Hospitalization Study, INSIGHT Protocol No. 003) opened in September 2009 as the H1N1v Hospitalization Study (FLU 003). The initial purpose was to consecutively enroll individuals locally diagnosed with influenza A who were hospitalized with complications or severe disease at times when the pandemic 2009 H1N1 influenza virus was broadly circulating in their geographic area and to follow their clinical course over 60 days following enrollment. In June 2011 the protocol was amended to include enrollment of patients with a diagnosis of influenza (confirmed or suspected), irrespective of type or subtype, who are hospitalized with complications or severe disease. In August 2013, the protocol was further expanded to include participants with a suspected or confirmed diagnosis of a targeted non-influenza viral respiratory infection, e.g., MERS-CoV, in addition to confirmed or suspected influenza (of any type).
The existing infrastructure and resources for FLU 003 Plus are being leveraged to include participants who are SARS-CoV-2 infected. This report addresses the incremental efforts to enroll COVID-19 participants into the observational Respiratory Virus Hospitalization Study.
As of mid-August 2020, 450 COVID patients had been enrolled in the observational study to estimate rates of morbidity and mortality and to examine predictors of severity among participants with SARS-CoV-2 infection.
Terms: <2019 novel coronavirus><2019-nCoV><21+ years old><Address><Adult><Adult Human><COVID><China><Clinical><Clinical Research><Clinical Study><CoV disease><Coronaviridae><Coronavirus><Diagnosis><Disease><Disorder><Enrollment><Geographic Area><Geographic Locations><Geographic Region><Geographical Location><Grippe><H1N1><H1N1 Virus><Hospital Admission><Hospitalization><Individual><Infection><Influenza><Influenza A><Influenza A Virus, H1N1 Subtype><Influenza A virus><Influenza B><Influenza B Virus><Influenza Virus><Influenza Viruses Type A><Influenza Viruses Type B><Influenzavirus A><Infrastructure><International><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Mainland China><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Morbidity><Morbidity - disease rate><NIAID><National Institute of Allergy and Infectious Disease><Observation research><Observation study><Observational Study><Observational research><Orthomyxovirus Type A><Orthomyxoviruses Type B><Participant><Patients><Protocol><Protocols documentation><Public Health><Reporting><Research Resources><Resources><SARS Virus><SARS corona virus><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV-2><SARS-CoV2><SARS-Related Coronavirus><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe acute respiratory syndrome coronavirus 2><Severities><Time><Type A Influenza><Viral Diseases><Viral Respiratory Tract Infection><Virus Diseases><Wuhan coronavirus><adulthood><corona virus><corona virus disease><coronavirus disease><enroll><flu infection><geographic site><influenza infection><influenzavirus><mortality><novel><pandemic><pandemic disease><respiratory virus><seasonal flu><seasonal influenza><severe acute respiratory syndrome-CoV><viral infection><viral respiratory infection><virus infection><virus-induced disease>